Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts provided a 12-month price target range of $23.00 to $30.00, with an average target of $27.00, down from a previous average of $29.75. The company, a clinical-stage biopharmaceutical firm, reported a 34.48% revenue growth rate but faces challenges with a negative net margin and ROA.
October 03, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcus Biosciences received mixed analyst ratings, with a majority being somewhat bullish. The 12-month price target range is $23.00 to $30.00, with an average target of $27.00, down from $29.75. The company reported a 34.48% revenue growth rate but faces challenges with a negative net margin and ROA.
The mixed analyst ratings suggest a neutral short-term impact on the stock price. The somewhat bullish sentiment is offset by the decline in average price target and financial challenges such as negative net margin and ROA. The company's strong revenue growth is a positive factor, but the overall impact is balanced by the financial difficulties.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100